Linked Life Data

7061177

Source:http://linkedlifedata.com/resource/pubmed/id/7061177

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-5-12
pubmed:abstractText
We have developed a new model to test the in vivo functions of NK cells. Injection of B6 mice with as little as 25 microliter of an NK-specific alloantiserum, anti-NK 1.1, significantly reduced the recipient's NK activity. The reduction, monitored in vitro as a decrease in the ability of spleen cells (SC) to lyse 51Cr-labelled YAC-1 target cells, occurred rapidly, within 2 h of administration of the anti-NK 1.1 serum. NK activity gradually returned to control levels but still was significantly depressed at 48 h. Comparable decreases were observed whether the serum was injected by the intravenous (i.v.) or the intraperitoneal (i.p.) route. Injection of the mice with exogenous complement (newborn rabbit serum) did not significantly increase the antiserum's effect. To test the requirement for NK cells in tumor clearance in vivo, mice were pre-treated with anti-NK 1.1 serum and subsequently injected i.v. with 125IdUrd (5-iodo 2'deoxyuridine)-labelled YAC-1 or RBL-5 lymphoma cells. Tumor cell clearance in lungs, liver and spleen was reduced two to four-fold in the anti-serum-treated mice compared to injection controls. These results provide direct evidence that NK cells are involved in the elimination of tumor cells in vivo.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
203-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
In vivo reduction of NK activity with anti-NK 1 serum: direct evaluation of NK cells in tumor clearance.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.